Herpes vector-mediated delivery of marker genes to disseminated central nervous system tumors.
The present study investigated the ability of a recombinant herpes simplex virus type 1 (HSV) vector to deliver genes into disseminated brain tumor foci through intrathecal injection of the vector. The animal model was designed to simulate brain tumors with cerebrospinal fluid (CSF) metastases, which are found especially in the pediatric population. 9L gliosarcoma cells were injected both into the right frontal lobe and in through the cisterna magna of adult rats. The HSV vector, hrR3, was inoculated intrathecally 5 days later. This vector is defective in the gene for ribonucleotide reductase, and, therefore, replicates preferentially in dividing cells; it retains an intact HSV-thymidine kinase gene (HSV-tk). Two days after injection of the vector, immunohistochemical staining for HSV thymidine kinase (HSV-TK) revealed expression in frontal tumors, as well as in leptomeningeal tumor foci along the entire neuroaxis. HSV-TK-immunopositive cells were most frequent in small tumors contacting the CSF pathways. Frontal lobe tumors showed the highest density of HSV-TK-immunopositive cells around their periphery with little expression in central parts. Some paraventricular neurons temporarily showed HSV-TK-immunolabeling at this early time point. The number of HSV-TK-immunopositive tumor cells markedly decreased 5 days after injection of the HSV vector. In all animals, some toxicity was observed in the first 2-4 days after virus injection with extensive leptomeningeal inflammation. In conclusion, intrathecal application of HSV vectors can mediate widespread transfer of the therapeutic HSV-tk gene into disseminated tumors throughout the brain and CSF pathways. Although there was marked toxicity associated with intrathecal injection of this vector, this mode of gene delivery offers a promising approach for treatment of CSF-metastases in conjunction with development of less toxic vectors.
Kramm
C M
CM
Neuroscience Center, Massachusetts General Hospital, Boston 02129, USA.
Rainov
N G
NG
Sena-Esteves
M
M
Chase
M
M
Pechan
P A
PA
Chiocca
E A
EA
Breakefield
X O
XO
D000818:Animals; D016543:Central Nervous System Neoplasms / Q000473:pathology / Q000628:therapy*; D002946:Cisterna Magna; D005625:Frontal Lobe; D017930:Genes, Reporter; D005813:Genes, Synthetic; D005822:Genetic Vectors / Q000235:genetics*; D018316:Gliosarcoma / Q000473:pathology / Q000556:secondary* / Q000628:therapy; D007278:Injections, Spinal; D008297:Male; D008577:Meningeal Neoplasms / Q000473:pathology / Q000556:secondary* / Q000628:therapy; D009362:Neoplasm Metastasis; D009368:Neoplasm Transplantation; D051381:Rats; D011916:Rats, Inbred F344; D011994:Recombinant Proteins / Q000032:analysis; D018139:Simplexvirus / Q000235:genetics* / Q000472:pathogenicity / Q000502:physiology; D013346:Subarachnoid Space; D013937:Thymidine Kinase / Q000032:analysis / Q000096:biosynthesis / Q000235:genetics; D014162:Transfection; D014779:Virus Replication; D001616:beta-Galactosidase / Q000032:analysis / Q000096:biosynthesis / Q000235:genetics
D011994:Recombinant Proteins; D013937:Thymidine Kinase; D001616:beta-Galactosidase